atazanavir sulfate has been researched along with Acute Liver Injury, Drug-Induced in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barreiro, P; Fernández-Montero, JV; Labarga, P; Soriano, V; Vispo, E | 1 |
| Camacho, A; Pérez-Camacho, I; Rivero, A; Torre-Cisneros, J | 1 |
| Altice, F; Botsko, M; Egan, JE; Fiellin, DA; Nandi, V; O'Connor, PG; Sullivan, LE; Tozzi, MJ; Vergara-Rodriguez, P | 1 |
| Sulkowski, MS | 1 |
| Eholié, SP; Girard, PM; Lacombe, K; Serfaty, L; Wendum, D | 1 |
| Abdel-kader, L; Cano, P; Lozano, F; Márquez, M; Mira, JA; Palacios, R; Pineda, JA; Rivero, A; Santos, J; Torre-Cisneros, J | 1 |
1 review(s) available for atazanavir sulfate and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
[Safety of atazanavir in patients with HIV and hepatitis B and/or C virus coinfection].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Cohort Studies; Disease Progression; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis D, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Insulin Resistance; Liver; Liver Cirrhosis; Multicenter Studies as Topic; Oligopeptides; Pyridines | 2008 |
5 other study(ies) available for atazanavir sulfate and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patients.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Coinfection; Cyclopropanes; Darunavir; Female; Follow-Up Studies; Hepatitis C; HIV Infections; Humans; Liver; Male; Nevirapine; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2013 |
Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Chemical and Drug Induced Liver Injury; Cohort Studies; Dose-Response Relationship, Drug; Drug Interactions; HIV Infections; Humans; Naloxone; Oligopeptides; Opioid-Related Disorders; Pyridines | 2011 |
Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Chemical and Drug Induced Liver Injury; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Indinavir; Oligopeptides; Pyridines | 2004 |
Acute hepatic cytolysis in an HIV-infected patient taking atazanavir.
Topics: Acute Disease; Atazanavir Sulfate; Chemical and Drug Induced Liver Injury; Female; HIV Infections; HIV Protease Inhibitors; Humans; Middle Aged; Oligopeptides; Pyridines | 2004 |
Low incidence of severe liver toxicity in patients receiving antiretroviral combinations including atazanavir.
Topics: Adult; Anti-Retroviral Agents; Atazanavir Sulfate; Chemical and Drug Induced Liver Injury; Female; Humans; Incidence; Male; Middle Aged; Oligopeptides; Pyridines; Spain | 2006 |